Treatment of exudative age-related macular degeneration with intravitreal ranibizumab in clinical practice: a 3-year follow-up

PURPOSE: To evaluate the 36-month efficacy of intravitreal ranibizumab injections for choroidal neovascularization secondary to age-related macular degeneration (AMD) in real world clinical practice. METHODS: Retrospective study involving 84 eyes of 77 patients; 52 eyes completed 3 years of follow-up. Subjects were observed initially on a monthly basis and with extended follow-up intervals if signs of quiescence were detected, according to an established protocol. A comprehensive ophthalmologic examination was performed, including best-corrected visual acuity (BCVA) determined with Early Treatment Diabetic Retinopathy Study charts, stereoscopic macular biomicroscopy and optical coherence tomography (OCT) with fluorescein angiography and indocyanine green angiography if considered necessary. Treatment was given if signs of active lesions were present. RESULTS: The mean baseline BCVA was 49.33 and 49.52 letters at the 36-month visit. The average of treatments was 8.6 at 3 years. At this time point, 77% of treated eyes stabilized or improved their vision (VA loss ≤ 5 letters). A predictive value for better VA was found for younger age, better baseline VA, good response on OCT and more frequent treatments. CONCLUSION: At 3 years, intravitreal ranibizumab is able to maintain baseline VA in exudative AMD patients, with a reduced number of injections, but not to show VA improvement, in clinical practice.info:eu-repo/semantics/publishedVersio

Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy

PURPOSE: To evaluate morphological and functional chorioretinal changes 5 years after standard photodynamic therapy (PDT) for chronic central serous chorioretinopathy (CSC). METHODS: A retrospective, nonrandomized study, including patients with chronic CSC treated with standard PDT and followed for at least 60 months. All patients underwent a complete ophthalmological examination, and the location and number of treatments were registered. Five or more years after treatment, subfoveal and non-subfoveal treated areas were evaluated with Spectralis optical coherence tomography and microperimetry. RESULTS: Seventeen eyes of 15 patients were included, with mean age of 48.3 ± 8.4 years and a mean follow-up of 80.6 ± 12.4 months (range from 62 to 104 months). All eyes had neurosensory detachment (NSD) at baseline. Treatment was performed under the fovea in 58.8 % and in a non-foveal area in 41.2 % of the eyes. At the final visit all eyes had resolution of the NSD, with a statistical significant reduction in central macular thickness (p = 0.005) and preserved neuroretinal thickness (p = 0.839). There was a statistical difference between initial and final BCVA (p < 0.001) and a mean gain of 8.4 ± 7.8 letters. Subfoveal morphological changes in external limiting membrane (ELM) and in photoreceptor inner and outer segment junction (IS/OS) were correlated with final BCVA (p = 0.015 and p = 0.014 respectively), but not with the variation of BCVA. There was a statistical correlation between morphological changes in IS/OS line and retinal sensitivity in the central 12° and 2° (p = 0.003 and p = 0.002 respectively). The morphological changes in the subfoveal layers were not dependent on treatment location (p = 0.154, p = 0.644, and p = 1.0 for ELM, IS/OS line, and retinal pigment epithelium respectively). Subfoveal final mean choroidal thickness was 295.1 ± 68.7 μm, and showed no statistical difference from the normal population (p = 0.633). CONCLUSIONS: Morphological and functional chorioretinal changes, observed 5 or more years after standard PDT for chronic CSC, were not correlated with the location of treatment, neither with the progression of visual acuity or with the location of treatment, and are more likely to be related to the disease itself than with the treatment provided.info:eu-repo/semantics/publishedVersio

Estabilidade de linhagens de feijoeiro comum de grão preto no ensaio intermediário/2005 da Embrapa Arroz e Feijão.

O objetivo foi avaliar a estabilidade e adaptabilidade de linhagens de grão preto no ensaio intermediário/2005 do programa de melhoramento genético do feijoeiro comum da Embrapa Arroz e Feijão e identificar as mais promissoras para ambientes favoráveis e desfavoráveis

BRS Requinte: nova cultivar de feijoeiro comum de tipo de grão carioca com retardamento do escurecimento do grão.

A cultivar BRS Requinte originou-se do cruzamento Carioca MG // POT 94 / AN910523, realizado pela Embrapa Arroz e Feijão.bitstream/CNPAF/21540/1/comt_65.pd

Estabilidade de linhagens de feijoeiro comum de grão carioca no ensaio intermediário/2005 da Embrapa Arroz e Feijão.

O objetivo foi avaliar a estabilidade e adaptabilidade de linhagens de grão carioca no ensaio intermediário/2005 do programa de melhoramento genético do feijoeiro comum da Embrapa Arroz e Feijão e identificar as mais promissoras para ambientes favoráveis e desfavoráveis

BRS Grafite: cultivar de feijoeiro comum de grão preto, indicada para as regiões Sudeste e Centro-Oeste do Brasil.

A cultivar BRS Grafite originou-se do cruzamento entre as linhagens AN 512567 x México 168, realizado na Embrapa Arroz e Feijão em 1986.bitstream/CNPAF/21538/1/comt_63.pd

Severidade média da mancha angular em ensaios de VCU no período 2003-2009.

O objetivo deste trabalho foi estimar a severidade média da mancha angular em cultivares suscetíveis, em diferentes municípios, safras, e anos de cultivo.Pôster - pós-graduação

BRSMG Pioneiro: nova cultivar de feijoeiro comum de grãos tipo carioca com alelos de resistência à antracnose e ferrugem, indicada para o Sul do Brasil.

A cultivar BRSMG Pioneiro, além de possuir grãos tipo carioca, apresenta como principal vantagem a resistência a vários patótipos de antracnose e ferrugem, sendo uma excelente opção para os produtores de feijão carioca da região Sul do país, nos plantios da safra e safrinha.bitstream/CNPAF/23578/1/comt_113.pd